Rimstar 150+75+400+275 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

rimstar 150+75+400+275 mg filmovertrukne tabletter

orifarm a/s - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg

Suxamethonium chloride "Aguettant" 10 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

suxamethonium chloride "aguettant" 10 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte

laboratoire aguettant - suxamethoniumchlorid (vandfrit) - injektionsvæske, opløsning i fyldt injektionssprøjte - 10 mg/ml

Rifampar 150+75+400+275 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

rifampar 150+75+400+275 mg filmovertrukne tabletter

paranova danmark a/s - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg

Qinlock Den Europæiske Union - dansk - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinale stromale tumorer - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Ozawade Den Europæiske Union - dansk - EMA (European Medicines Agency)

ozawade

bioprojet pharma - pitolisant - sleep apnea, obstructive - andre narkotika stoffer - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Sorafenib Accord Den Europæiske Union - dansk - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiske midler - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Pyrukynd Den Europæiske Union - dansk - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Lapatinib "Newbury" 250 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

lapatinib "newbury" 250 mg filmovertrukne tabletter

newbury pharmaceuticals ab - lapatinibditosylatmonohydrat - filmovertrukne tabletter - 250 mg